Stock-Based Compensation - Restricted Stock (Details) - USD ($) |
6 Months Ended | |
|---|---|---|
Mar. 31, 2022 |
Sep. 30, 2021 |
|
| Stock-Based Compensation | ||
| Weighted-average years expected to be recognized over | 1 year 6 months | |
| Unvested restricted stock | ||
| Stock-Based Compensation | ||
| Unvested, Beginning balance | 0 | |
| Granted | 4,441 | |
| Vested | 4,441 | |
| Unvested, Ending balance | 0 | |
| Total unrecognized expense remaining | $ 0 | |
| Weighted-average years expected to be recognized over | 0 years | |
| Weighted Average Grant Date Fair Value Price | ||
| Unvested, Beginning balance | $ 0 | $ 0 |
| Granted | 3.94 | |
| Vested | 3.94 | |
| Unvested, Ending balance | $ 0 | 0 |
| Restricted stock units | ||
| Stock-Based Compensation | ||
| Unvested, Beginning balance | 10,000 | |
| Forfeited | (10,000) | |
| Weighted Average Grant Date Fair Value Price | ||
| Unvested, Beginning balance | 5.09 | |
| Forfeited | $ 5.09 | |
| Unvested, Ending balance | $ 5.09 |
| X | ||||||||||
- Definition Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options outstanding. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of options vested. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|